Maryia Zhdanava

9PUBLICATIONS
2CO-AUTHORS
Labour, migration and developmentMajor global burdens of diseaseMedical molecular engineering of nucleic acids and proteinsPsychiatry (incl. psychotherapy)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 15, 2025
Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray.

Kristin Clemens, Maryia Zhdanava, Amanda Teeple

|Jan 19, 2025
Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA.

Manish K Jha, Maryia Zhdanava, Aditi Shah

|Jul 13, 2024
Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective.

Maryia Zhdanava, Jacqueline Pesa, Porpong Boonmak

|May 10, 2024
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States.

Lisa Harding, Kruti Joshi, Maryia Zhdanava

|Sep 06, 2023
Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States.

Maryia Zhdanava, Ruizhi Zhao, Ameur M Manceur

|May 02, 2023
Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.

Maryia Zhdanava, Amanda Teeple, Dominic Pilon

Pageof 2

Frequent Collaborators

3 joint publications

Dominic Pilon

1 joint publications

Ameur M Manceur